91results about "DsRNA viruses" patented technology

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.

The invention relates to a novel fish virus, indicated to be a Totivirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

The present invention relates to a combination vaccine comprising the antigens: a) Cryptosporidium parvum gp40; b) inactivated bovine rotavirus; c) inactivated bovine coronavirus; and d) E. coli fimbrial adhesins F5 and F41. In addition, the invention relates to methods for the preparation of the vaccine, methods for vaccinating ruminants against infection by Cryptosporidium parvum, bovine rotavirus, bovine coronavirus and E. coli, and to a kit-of-parts at least comprising a container comprising the at least one antigen according to the invention.

Attenuated isolates of avian reoviruses associated viral arthritis / tenosynovitis in poultry are presented, including avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077 and progeny or derivatives thereof and avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or compositions as vaccines to control of reovims-induced viral arthritis / tenosynovitis in birds of the order Galliformes are also presented.

The present invention describes immunogenic compositions containing immunogenic polypeptides of Porcine circovirus 2e, 3c, or 4 (PCV2e, PCV3c, or PCV4), including immunogenic compositions containing antigens other than PCV2e, PCV3c, or PCV4 antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating a PCV2e, PCV3c, or PCV4 infection are also described.

The invention discloses a pelteobagrus fulvidraco brain tissue cell line PYCB sensitive to viruses and application thereof, and belongs to the technical field of aquatic organism cell culture and disease prevention and control. The preservation number of the Pelteobagrus fulvidraco brain tissue cell line PYCB is CCTCC (China Center For Type Culture Collection) NO: C2025148. The Pelteobagrus fulvidraco brain tissue cell line PYCB is successfully constructed by taking the Pelteobagrus fulvidraco brain tissue as an object, and the cell line can be continuously and stably subcultured, is high in proliferation speed and simple in culture method, is sensitive to Pelteobagrus fulvidraco small RNA viruses and Pelteobagrus fulvidraco stem casing viruses, and can be used for isolated culture of viruses. The invention provides an important research platform and an experimental material for separating and identifying fish viruses and virus vaccines and developing medicines.

The present invention relates to a synthetic nucleic acid comprising, in the 5'-3'direction, the following elements: a) at least one 5'UTR untranslated region, selected from the 5'UTR of the human beta-globin gene (SEQ ID NO 4), the synthetic region 5'NeoUTR3 (SEQ ID NO 5), the 5'UTR of the human alpha-globin gene (SEQ ID NO 6), and the synthetic region 5'UTR4 (SEQ ID NO 7); b) an open reading frame (ORF); and c) at least one 3'UTR untranslated region, selected from the 3'UTR region of the VP6 gene of rotavirus (SEQ ID NO 1) and the 3'UTR region of the manganese superoxide dismutase (MnSOD) gene.

The application belongs to the technical field of animal cell engineering, and particularly relates to a pigeon fibroblast cell strain X4 and application thereof. A pigeon fibroblast cell strain is provided, which is named pigeon fibroblast cell X4, and the preservation number is CGMCC No. 46754. The pigeon fibroblast cell strain can be used for virus isolation or amplification, virus pathogenic mechanism research, and development of antiviral drugs and vaccines, and has a good application prospect in pigeon disease research.

The present disclosure provides a method for producing a negative-strand RNA virus vector. The present disclosure specifically provides a method for producing a negative-strand RNA virus vector in the presence of a PKR inhibitory factor.

Among the various aspects of the present disclosure is the provision of genetically modified Vero cells. The present teachings include compositions for a rotavirus reverse genetics system that can include SERPINB1 knockout cells combined with a helper plasmid. The present teachings also include a vaccine-producing cell substrate that can include Vero cells with disrupted TMEM236 and method of use thereof.

The present invention provides a mammalian cell line that has been genetically engineered to make it resistant to viral entry and / or replication; and provides a method for using the cell line to reduce or prevent viral contamination of a bioproduction system.

The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

The present invention provides recombinant herpesvirus of turkey (HVT) viral vectors comprising heterologous polynucleotides encoding avian influenza antigens. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines and can provide protection against avian influenza and other pathogens when administered to avians.

The invention relates to the technical field of biology, in particular to a porcine rotavirus and porcine epidemic diarrhea virus bivalent subunit vaccine and application thereof, and the active ingredient of the vaccine is an antigen protein combination composed of VP4, VP7 and S1 protein. The three proteins have a synergistic enhancement effect during combined immunization, and the S1 protein can cooperate with VP4 and VP7 antigens to significantly improve the early humoral immune response level. Besides, the antigen combination can induce an organism to generate high-level specific antibodies and virus neutralizing antibodies and stimulate remarkable cellular immune response, and has good application potential in the aspect of combined prevention and control of the porcine rotavirus and the porcine epidemic diarrhea virus.

The application belongs to the field of biological medicine, and provides a method for promoting transient overexpression of exogenous genes in fish based on PEI40000 and application of PEI40000 in enhancing protection rate of fish hemorrhagic disease virus DNA vaccine. The PEI40000 reagent provided by the application is convenient to store and stable in property; preparation and application operation are simple; the reagent can be directly added into a culture medium containing serum; the cost performance is high, and the reagent is suitable for large-scale transfection experiments; the application verifies that the method significantly promotes expression of an exogenous plasmid in fish, and makes the expression time effect have a higher overexpression level within 1-10 days; and it is also clear that the application significantly enhances the protection effect of the fish hemorrhagic disease virus DNA vaccine, and significantly improves the survival rate of diseased fish, and the effect is more significant than that of the common adjuvant in the prior art, and the application can become an effective adjuvant for various DNA vaccines, and has a wide application prospect.

The present invention relates to vaccine composition comprising inactivated rotavirus antigen, methods of inactivation and preparation of vaccine composition thereof. The present invention also discloses a combination vaccine comprising inactivated rotavirus antigen and norovirus antigen, and vaccine preparations thereof.

A production method for a crystal of a crystalline protein, the method including a step of inducing expression of a crystalline protein in Escherichia coli into which an expression construct of the crystalline protein has been introduced, and incubating the Escherichia coli for a predetermined time until a crystal of the crystalline protein is formed inside the Escherichia coli, and a crystal structure analysis method including a step of subjecting a crystal produced by the above-described production method to an X-ray crystal structure analysis together with the Escherichia coli, are useful as technologies for conveniently producing and analyzing a crystal of a protein.

The invention discloses an IBDV (Infectious Bursal Disease Virus) mutant based on VP1 protein T425 and R426 synergistic modification and application of the IBDV mutant. The invention identifies that threonine at the 425th site on the VP1 protein is a new phosphorylation site for the first time, and reveals that threonine at the 425th site and adjacent arginine methylation modification at the 426th site have a synergistic positive feedback regulation relationship. Based on the mechanism, a T425 and R426 double-site modification deleted virus mutant is successfully constructed, and the mutant shows a phenotype with severely weakened replication ability. In addition, the invention also provides an antibody capable of specifically recognizing pT425, an application of a GSK-3 kinase inhibitor in inhibition of virus replication, and a related screening and detection method. The invention provides a new target and strategy for developing novel IBDV attenuated vaccines, antiviral drugs and diagnostic reagents.

A vaccine composition comprising a virus antigen wherein the composition comprises less than 5% serum, wherein the virus antigen is a whole virus or derived from a whole virus. the vaccine composition reduces, prevents or avoids cross-stitch spinal deformity in the treated animal

The present application relates to the field of immunology, in particular to a vaccine diluent preparation method and application. The present application provides two fusion proteins, and the composition of the combination of the two fusion proteins can have the effect of improving the immune effect of the vaccine, effectively prolonging the immune duration of the vaccine, providing more efficient immune protection for the animal body, and the vaccine diluent production process is simple and low in cost.

The present invention relates to fusogenic peptide carrier molecules for delivery of therapeutic nucleic acid to cells and methods of use thereof for the treatment of a disease or disorder.

The present invention relates to a recombinant Kluyveromyces lactis (K. lactis) yeast strain capable of highly efficient expression of one or more heterologous proteins and suitable for use as a vaccine to elicit a protective immune response against pathogens. The present invention particularly provides a K. lactis strain for targeted cloning of nucleic acids encoding heterologous antigens into the yeast genome of the K. lactis strain, characterized in that the K. lactis strain contains an integrated expression cassette for the heterologous antigen at the KlURA3-20 locus (KLLA0E22771g) and / or KlMET5-1 locus (KLLA0B03938g) instead of or in addition to the KlLAC4 locus. The present invention also relates to an integrative expression vector and a method for producing the K. lactis strain of the present invention, as well as its use as a vaccine. [Selection diagram] None

Antigens, vaccines, and methods for treating fish against infection with piscine myocarditis virus (PMCV) are disclosed.

The application discloses a recombinant porcine rotavirus capable of simultaneously expressing different G type VP7s and a construction method and application thereof, and relates to the technical field of biotechnology. The construction method comprises the following steps: taking a G9 type porcine rotavirus as a skeleton, inserting a coding gene of a G5 type porcine rotavirus VP7 protein into a 3' end of an NSP1 gene open reading frame of the G9 type porcine rotavirus, inserting a coding gene of a G4 type porcine rotavirus VP7 protein into a 3' end of an NSP3 gene open reading frame of the G9 type porcine rotavirus, and packaging and constructing to obtain a recombinant porcine rotavirus capable of simultaneously expressing G4, G5 and G9 type VP7 proteins. Immunization of the recombinant porcine rotavirus can simultaneously induce high-level antibodies against the G4, G5 and G9 types, the antibodies have a long duration, and can passively protect animals against infection of the three G type rotaviruses.

The invention belongs to the technical field of animal cell engineering, and particularly relates to a pigeon fibroblast strain X4 and application thereof. The invention provides a pigeon fibroblast strain which is named as pigeon fibroblast X4 and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 46754. The pigeon fibroblast cell strain can be used for separation or amplification of viruses, research of pathogenic mechanisms of the viruses and development of antiviral drugs and vaccines, and has a good application prospect in pigeon disease research.

The invention belongs to the technical field of aquatic immunity and biological preparations, and discloses a mutant IL-7 protein and application of the mutant IL-7 protein as a grass carp reovirus inactivated vaccine adjuvant. The applicant obtains the IL-7 mutant mIL-7 with higher receptor binding capacity on the basis of grass carp IL-7. After the mIL-7 and the GCRV-II type inactivated vaccine are combined to immunize the grass carp, the expression of immune related genes is obviously up-regulated, the IL-10 is obviously reduced, the enzyme activities of CAT, ACP and Gpx in serum are also obviously improved, and the AST is obviously reduced. A challenge experiment result shows that the survival rate of the grass carp combined with the mIL-7 and the inactivated vaccine is increased by about 10%, and the VP56 virus load in the body is reduced. As an immunologic adjuvant, the mutant IL-7 can effectively enhance the specific immune response and disease resistance of the grass carp, can be used as an efficient and safe adjuvant of a grass carp inactivated vaccine, and has good safety and application prospects.

This invention discloses a fusion protein expressing novel duck reovirus σC protein and duck-derived goose parvovirus VP1 protein, a recombinant duck viral enteritis virus, a vaccine, its construction method, and its applications, belonging to the field of recombinant virus technology. The nucleotide sequence of the fusion protein is shown in positions 300-3568 of SEQ ID NO:1. The fusion protein of this invention can simultaneously express protective antigen proteins of novel duck reovirus (NDRV) and duck-derived goose parvovirus (DGPV). Using CRISPR / Cas9 gene editing technology, the fusion protein is recombined into the US3 gene of duck viral enteritis virus. The resulting recombinant duck viral enteritis virus not only provides protection against virulent duck viral enteritis virus challenge but also provides good protection against NDRV and DGPV, achieving a multi-protection effect with a single injection.

The invention discloses a rotavirus reassortment attenuated strain LG12 and application of the rotavirus reassortment attenuated strain LG12. The rotavirus reassortment attenuated strain LG12 comprises: i) a coding gene of a structural protein VP7 of a human G12 type rotavirus strain G12P [6]; and ii) coding genes of structural proteins VP1, VP2, VP3, VP4 and VP6 and non-structural proteins NSP1, NSP2, NSP3, NSP4 and NSP5 of the sheep rotavirus strain LLR. The reassortment strain provided by the invention has the safety of animal strains and the immunogenicity of human G12 type RV, can effectively prevent infection of human G12 type wild strains, and can have different degrees of cross protection on infection of other various G type RV wild strains; the method has great significance for developing RV vaccines which cover more G and P genotypes of Chinese epidemic RVA, have stronger prevention pertinence and provide a better protection effect on Chinese infantile diarrhea.